Marta Larráyoz

1.8k total citations
17 papers, 677 citations indexed

About

Marta Larráyoz is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Marta Larráyoz has authored 17 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Immunology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Marta Larráyoz's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Marta Larráyoz is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Marta Larráyoz collaborates with scholars based in United Kingdom, Spain and United States. Marta Larráyoz's co-authors include Jackeline Agorreta, Rubén Pı́o, Luis M. Montuenga, Jonathan C. Strefford, Andrew J. Steele, Francesco Forconi, Graham Packham, Mark S. Cragg, Matthew D. Blunt and Rachel Dobson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Marta Larráyoz

17 papers receiving 671 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marta Larráyoz United Kingdom 13 358 206 195 180 140 17 677
Cory Mavis United States 16 441 1.2× 159 0.8× 285 1.5× 120 0.7× 245 1.8× 74 754
Huifeng Niu United States 13 362 1.0× 149 0.7× 290 1.5× 251 1.4× 267 1.9× 17 783
Jennifer E. Amengual United States 15 574 1.6× 137 0.7× 408 2.1× 214 1.2× 450 3.2× 87 1.1k
Rosa I. Gallagher United States 15 413 1.2× 140 0.7× 345 1.8× 83 0.5× 74 0.5× 27 808
Aizhen Xiao United States 15 393 1.1× 170 0.8× 189 1.0× 84 0.5× 80 0.6× 21 773
Jianning Yang United States 14 320 0.9× 254 1.2× 220 1.1× 125 0.7× 237 1.7× 29 693
Michel Maira Switzerland 8 629 1.8× 124 0.6× 269 1.4× 40 0.2× 124 0.9× 12 837
Gary Borzillo United States 12 492 1.4× 93 0.5× 169 0.9× 147 0.8× 93 0.7× 24 737
Elisabeth Llonch Switzerland 2 509 1.4× 94 0.5× 214 1.1× 40 0.2× 106 0.8× 2 651
Phong Quang United States 13 785 2.2× 185 0.9× 304 1.6× 175 1.0× 137 1.0× 31 1.2k

Countries citing papers authored by Marta Larráyoz

Since Specialization
Citations

This map shows the geographic impact of Marta Larráyoz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Larráyoz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Larráyoz more than expected).

Fields of papers citing papers by Marta Larráyoz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Larráyoz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Larráyoz. The network helps show where Marta Larráyoz may publish in the future.

Co-authorship network of co-authors of Marta Larráyoz

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Larráyoz. A scholar is included among the top collaborators of Marta Larráyoz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Larráyoz. Marta Larráyoz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Celay, Jon, María V. Revuelta, Marta Larráyoz, et al.. (2023). Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas. Blood. 142(Supplement 1). 431–431. 2 indexed citations
2.
Valencia, Karmele, Cristina Sainz, Cristina Bértolo, et al.. (2021). Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma. Disease Models & Mechanisms. 15(1). 5 indexed citations
3.
Johnston, Harvey E., Matthew Carter, Marta Larráyoz, et al.. (2018). Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation. Molecular & Cellular Proteomics. 17(4). 776–791. 46 indexed citations
4.
Blakemore, Stuart J., Ruth Clifford, Pavlos Antoniou, et al.. (2017). The contribution of gene mutations to long-term clinical outcomes: data from the randomised UK LRF CLL4 trial. ePrints Soton (University of Southampton). 2 indexed citations
5.
Blunt, Matthew D., Stefan Koehrer, Rachel Dobson, et al.. (2016). The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(9). 2313–2324. 54 indexed citations
6.
Azpilikueta, Arantza, Jackeline Agorreta, Sara Labiano, et al.. (2016). Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD-1 and Anti-CD137 Monoclonal Antibodies. Journal of Thoracic Oncology. 11(4). 524–536. 47 indexed citations
7.
Rose‐Zerilli, Matthew, Jane Whitney Gibson, Jun Wang, et al.. (2016). Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease. Leukemia. 30(6). 1301–1310. 22 indexed citations
8.
Aguilar-Hernández, Montserrat, Matthew D. Blunt, Rachel Dobson, et al.. (2016). IL-4 enhances expression and function of surface IgM in CLL cells. Blood. 127(24). 3015–3025. 69 indexed citations
9.
D’Avola, Annalisa, Ian Tracy, Laura Chiecchio, et al.. (2016). Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. Blood. 128(6). 816–826. 42 indexed citations
10.
Larráyoz, Marta, Stuart J. Blakemore, Rachel Dobson, et al.. (2015). The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Leukemia. 30(2). 351–360. 83 indexed citations
11.
Grbeša, Ivana, María J. Pajares, Elena Martínez‐Terroba, et al.. (2015). Expression of Sirtuin 1 and 2 Is Associated with Poor Prognosis in Non-Small Cell Lung Cancer Patients. PLoS ONE. 10(4). e0124670–e0124670. 64 indexed citations
12.
13.
Blunt, Matthew D., Matthew Carter, Marta Larráyoz, et al.. (2015). The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model. Blood. 125(26). 4032–4041. 34 indexed citations
14.
Agorreta, Jackeline, Domenico Delia, Helen Turley, et al.. (2014). TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC. Molecular Cancer Research. 12(5). 660–669. 63 indexed citations
15.
Larráyoz, Marta, Rubén Pı́o, María J. Pajares, et al.. (2014). Contrasting responses of non‐small cell lung cancer to antiangiogenic therapies depend on histological subtype. EMBO Molecular Medicine. 6(4). 539–550. 18 indexed citations
16.
Pajares, María J., Jackeline Agorreta, Marta Larráyoz, et al.. (2012). Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. Journal of Clinical Oncology. 30(10). 1129–1136. 62 indexed citations
17.
Catena, Raúl, Leyre Larzábal, Marta Larráyoz, et al.. (2010). VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A. Molecular Cancer. 9(1). 320–320. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cory Mavis Breakdown of academic impact, for papers by Huifeng Niu Breakdown of academic impact, for papers by Jennifer E. Amengual Breakdown of academic impact, for papers by Rosa I. Gallagher Breakdown of academic impact, for papers by Aizhen Xiao Breakdown of academic impact, for papers by Jianning Yang Breakdown of academic impact, for papers by Michel Maira Breakdown of academic impact, for papers by Gary Borzillo Breakdown of academic impact, for papers by Elisabeth Llonch Breakdown of academic impact, for papers by Phong Quang
Rankless by CCL
2026